Allakos Inc. (ALLK)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allakos Inc. (“Allakos” or “the Company”) (NASDAQ: ALLK). Investors who purchased Allakos securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Allakos has violated federal securities laws.

Investigation Details:

On January 16, 2023, Allakos issued a press release “announc[ing] a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs.” The Company stated that it “will halt lirentelimab-related activities across clinical, manufacturing, research and administrative functions” and, “[a]s a result, the Company will reduce its workforce by approximately 50%.” On this news, Allakos’s stock price fell $1.80 per share, or 60.2%, to close at $1.19 per share on January 16, 2023.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Allakos securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | [email protected]